Expert Insights from PALOMA-3: Highlights from ASCO 2024

Opinion
Video

Wade T. Iams, MD, outlines insights gleaned from recently presented data from the PALOMA-3 trial in advanced EGFR-mutant non–small cell lung cancer.

Video content above is prompted by the following:

  • Briefly comment on key data from PALOMA and PALOMA-3 recently presented at ASCO 2024.
Recent Videos
6 experts are featured in this series.
6 experts are featured in this series.
6 experts are featured in this series.
6 experts are featured in this series.
The 2 main pafolacianine components, a folate analog and a dye, are commonly used in other medical applications.
An intravenous infusion administered prior to surgery enables treatment to occur in a normal time frame without the need for additional procedural time.
1 expert in this video
1 expert in this video
1 expert in this video
1 expert in this video
Related Content
Seattle-based Clinicians on Effective Treatment Combos in EGFR-Mutated NSCLC

Seattle-based Clinicians on Effective Treatment Combos in EGFR-Mutated NSCLC

ONCOLOGY Staff
January 17th 2025
Article

A panel of experts met to discuss the best treatment options for patients with EGFR or TP53-mutated non–small cell lung cancer.

Terence T. Sio, MD, MS, highlights advances such as proton beam radiotherapy that may improve outcomes for those with non–small cell lung cancer.

Optimizing NSCLC Outcomes Via Technological Advances in Radiation Oncology

Terence T. Sio, MD, MS
June 3rd 2024
Podcast

Terence T. Sio, MD, MS, highlights advances such as proton beam radiotherapy that may improve outcomes for those with non–small cell lung cancer.

NSCLC Experts Ponder Best First-Line Treatment Options

NSCLC Experts Ponder Best First-Line Treatment Options

ONCOLOGY Staff
January 17th 2025
Article

The discussion on NSCLC narrowed in on findings from recent clinical trials, particularly involving a combination regimen of amivantamab plus lazertinib vs osimertinib and chemotherapy.

Richard Lazzaro, MD, discusses how a robot-assisted platform has impacted his thoracic surgery and highlights other potential advancements in the field.

Moving The Needle in Lung Cancer Management With Robotic-Assisted Surgery

Richard Lazzaro, MD
April 22nd 2024
Podcast

Richard Lazzaro, MD, discusses how a robot-assisted platform has impacted his thoracic surgery and highlights other potential advancements in the field.

Mayo Clinic on AE Management Strategies for EGFR-Mutated NSCLC

Mayo Clinic on AE Management Strategies for EGFR-Mutated NSCLC

ONCOLOGY Staff
January 17th 2025
Article

The combination of amivantamab plus lazertinib has emerged as a potential treatment option for patients with EGFR-mutated NSCLC and has shown sufficient efficacy responses.

Low ctDNA Levels are Prognostic of Outcomes in Early-Stage Lung Adenocarcinoma

Low ctDNA Levels are Prognostic of Outcomes in Early-Stage Lung Adenocarcinoma

Tim Cortese
January 15th 2025
Article

The NeXT Personal platform identified minuscule amounts of ctDNA that were found to be predictive of OS and RFS outcomes in patients with lung adenocarcinoma.